Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Manuel Cobo-Dols"'
Autor:
Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/6b475fde214d41829d313ffd4989b729
Autor:
Li Zhang, Goetz Kloecker, Christian Rolfo, Wallace Akerley, Miklos Pless, Lubos Petruzelka, Zoran Andric, Joachim Aerts, Libor Havel, Jeffrey Ward, Richard Greil, David E Gerber, Janusz Milanowski, Angelo Delmonte, Sujith Kalmadi, Rodryg Ramlau, Rupesh Kotecha, Corey Langer, Ticiana A Leal, Manuel Cobo Dols, Jaromír Roubec, Thierry Berghmans, Rajiv Panikkar, Michael Eaton, Mussawar Iqbal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d606e4f0232746d8b3133a817cfbb80c
Autor:
Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100461- (2023)
Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic
Externí odkaz:
https://doaj.org/article/283d0b24db6b460b8d6628f029ba7cc0
Autor:
Begoña Campos‐Balea, Javier deCastro Carpeño, Bartomeu Massutí, David Vicente‐Baz, Diego Pérez Parente, Pedro Ruiz‐Gracia, Leonardo Crama, Manuel Cobo Dols
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3357-3364 (2020)
Background Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC in real‐world clinical practice. Meth
Externí odkaz:
https://doaj.org/article/4bf6361d299944fa992649aabb369d44
Autor:
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by
Externí odkaz:
https://doaj.org/article/559690e73ee44470a728f1e9dd145ed5
Autor:
Barragán, Javier Oliver, Juan Luis Onieva, María Garrido-Barros, Manuel Cobo-Dols, Beatriz Martínez-Gálvez, Ana Isabel García-Pelícano, Jaime Dubbelman, José Carlos Benítez, Juan Zafra Martín, Alejandra Cantero, Elisabeth Pérez-Ruiz, Antonio Rueda-Domínguez, Isabel
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3357
The present study aimed to investigate the potential of basal cell-free fluorometric DNA (cfDNA) quantification as a prognostic biomarker in advanced non-small cell lung cancer (NSCLC) patients treated with an Immune Checkpoint Blockade (ICB). A disc
Autor:
Zoran Andric, Gabriella Gálffy, Manuel Cobo Dols, Barna Szima, Goran Stojanovic, Marina Petrovic, Enriqueta Felip, David Vicente Baz, Santiago Ponce Aix, Oscar Juan-Vidal, Zsuzsanna Szalai, Gyorgy Losonczy, Antonio Calles Blanco, Reyes Bernabe, Gema García Ledo, Andrés Aguilar Hernández, Klaus Duecker, Dongli Zhou, Andreas Schroeder, Guelseren Guezel, Fortunato Ciardiello
Publikováno v:
Scientia
Avelumab; Cetuximab; Non–small cell lung cancer Avelumab; Cetuximab; Càncer de pulmó de cèl·lules no petites Avelumab; Cetuximab; Cáncer de pulmón de células no pequeñas Introduction We present the results of a phase 2a trial of first-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb98f97658e063447935929e1c8745e
https://hdl.handle.net/11351/9109
https://hdl.handle.net/11351/9109
Autor:
Javier Oliver, Juan Luis Onieva, Maria Garrido-Barros, Miguel Berciano-Guerrero, Alfonso Sánchez, Maria Jose Lozano, Angela Farngren, Martina Álvarez, Beatriz Martinez-Galvez, Elisabeth Pérez, Emilio Alba, Manuel Cobo-Dols, Antonio Rueda-Dominguez, Isabel Barragán
Cutaneous Melanoma (CM) is the most lethal form of skin cancer if it becomes metastatic, where treatment options and survival chances decrease dramatically. Immunotherapy treatments based on the immunologic checkpoint inhibitors (PD-1 and CTLA4) cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1dcf8c612331486d94736cdc7af81cb
Autor:
Juan Luis Onieva, Qingyang Xiao, Miguel Berciano-Guerrero, Aurora Laborda-Illanes, Carlos De Andrea, Patricia Cháves, Pilar Piñeiro, Alicia Garrido-Aranda, Elena Gallego, Belén Sojo, Laura Gálvez, Rosario Chica-Parrado, Daniel Prieto, Elisabeth Pérez-Ruiz, Angela Farngren, María José Lozano, Martina Álvarez, Pedro Jiménez, Alfonso Sánchez, Javier Oliver, Manuel Cobo-Dols, Emilio Alba, Isabel Barragán
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy that otherwise demonstrates durable responses with acceptable toxicity scores. This limitation is exacerbated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fde208d25243f6fb6d4589ffa419142
Autor:
Carmen Beato Zambrano, Antonio Javier Jiménez López, Anna Librán Oriol, Gala Serrano Bermúdez, Oliver Higuera Gómez, Pilar Torres, Jose L. Perez, Almudena Sanz Yagüe, Alfredo Paredes Lario, Rodolfo Chicas Sett, Manuel Cobo Dols, Ibone Huerta González, María Isabel Blancas López-Barajas, Alexandra Giraldo Marín, Pedro Sánchez Mauriño, Luis Cabezón Gutiérrez, Diana Moreno Muñoz, Begoña Soler López, Ignacio Delgado Mingorance, Francisco Javier García Navalón
Publikováno v:
BMJ Supportive & Palliative Care
Dipòsit Digital de la UB
Universidad de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
ObjectivesOpioid-induced constipation (OIC) can affect up to 63% of all patients with cancer. The objectives of this study were to assess quality of life as well as efficacy and safety of naloxegol, in patients with cancer with OIC.MethodsAn observat